{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:03:19Z","timestamp":1779948199125,"version":"3.53.1"},"reference-count":61,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"unspecified","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"End Kids Cancer Foundation","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Invenra Inc.","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"DOI":"10.13039\/100008258","name":"Hyundai Hope On Wheels","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015982","name":"Midwest Athletes Against Childhood Cancer","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100015982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002730","name":"Children\u2019s Neuroblastoma Cancer Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100002730","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The University of Wisconsin Carbone Cancer Center","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"DOI":"10.13039\/100001395","name":"Wisconsin Alumni Research Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100001395","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stand Up 2 Cancer","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Band of Parents","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"DOI":"10.13039\/100001445","name":"Alex\u2019s Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"St. Baldrick\u2019s Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"name":"HESI-Thrive","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["P01 CA250972"],"award-info":[{"award-number":["P01 CA250972"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R35-CA197078"],"award-info":[{"award-number":["R35-CA197078"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013851","name":"Pablove Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100013851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,9,23]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>Children and adults diagnosed with malignancies that are not curable in 2025 with surgery alone require multimodal therapy. For decades, this has included radiation therapy and\/or chemotherapy. This approach can be curative for many patients with certain cancers, such as acute lymphoblastic leukemia, Wilms tumor, Hodgkin\u2019s disease, and testicular cancer. For those who are not being cured, additional therapies are needed. The last 15 years have shown that those previously incurable patients are now having a chance for a cure using immunotherapy in the form of immune checkpoint inhibition (ICI). However, with the exception of rare patients with mutations in their DNA repair pathways associated with very high neoantigen loads, most patients receiving ICI therapy are not cured by it. This pertains to virtually all patients with some tumors, such as prostate or gastrointestinal (GI) cancers and even for a majority of those patients with advanced cancers classified as \u201cimmunogenic\u201d, such as melanoma, renal cell cancer, and lung cancer. One feature of these many patients not responding to ICI is that their tumors are immunologically cold. Namely, they are characterized by low actionable neoantigen load, low or absent major histocompatibility complex expression, and\/or an immune-hostile tumor microenvironment. These features are typical of high-risk neuroblastoma (HR-NBL). Despite its cold features, substantial progress has been made in advancing the treatment of HR-NBL using different forms of immunotherapy. This manuscript describes a clinical goal for HR-NBL for 20 years from now. In addition, it extrapolates from this experience and anticipated progress for HR-NBL to how these concepts might apply to improving treatments for patients with more common, yet cold, cancers of adults.<\/jats:p>","DOI":"10.1136\/jitc-2025-013267","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:35:18Z","timestamp":1761975318000},"page":"e013267","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["High-risk neuroblastoma as a model for immunotherapy of non-immunogenic cancers: where might we be in 20 years?"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0981-8875","authenticated-orcid":false,"given":"Paul M","family":"Sondel","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Wisconsin-Madison, Madison, Wisconsin, USA"},{"name":"Department of Human Oncology, University of Wisconsin Madison, Madison, Wisconsin, USA"},{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WIsconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2686-9500","authenticated-orcid":false,"given":"Alexander L","family":"Rakhmilevich","sequence":"additional","affiliation":[{"name":"Department of Human Oncology, University of Wisconsin Madison, Madison, Wisconsin, USA"},{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WIsconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israrul H","family":"Ansari","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Wisconsin-Madison, Madison, Wisconsin, USA"},{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WIsconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1175-4062","authenticated-orcid":false,"given":"Amy K","family":"Erbe","sequence":"additional","affiliation":[{"name":"Department of Human Oncology, University of Wisconsin Madison, Madison, Wisconsin, USA"},{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WIsconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2026052722304558000_13.10.e013267.1","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2023","journal-title":"Genes Dis"},{"key":"2026052722304558000_13.10.e013267.2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003743","article-title":"Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067","volume":"9","author":"Regan","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026052722304558000_13.10.e013267.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"2026052722304558000_13.10.e013267.4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133490","article-title":"The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge-A Systematic Review","volume":"15","author":"Perdyan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026052722304558000_13.10.e013267.5","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-21-1356","article-title":"Immunotherapy of Neuroblastoma: Facts and Hopes","volume":"28","author":"Anderson","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026052722304558000_13.10.e013267.6","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31831","article-title":"Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum","volume":"72","author":"DuBois","year":"2025","journal-title":"Pediatr Blood Cancer"},{"key":"2026052722304558000_13.10.e013267.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2009.11.011"},{"key":"2026052722304558000_13.10.e013267.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01375"},{"key":"2026052722304558000_13.10.e013267.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911123"},{"key":"2026052722304558000_13.10.e013267.10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1548292","article-title":"ADCC: the rock band led by therapeutic antibodies, tumor and immune cells","volume":"16","author":"Vincken","year":"2025","journal-title":"Front Immunol"},{"key":"2026052722304558000_13.10.e013267.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.11642"},{"key":"2026052722304558000_13.10.e013267.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910143411601"},{"key":"2026052722304558000_13.10.e013267.13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020309","article-title":"Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)","volume":"12","author":"Ladenstein","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026052722304558000_13.10.e013267.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3909"},{"key":"2026052722304558000_13.10.e013267.15","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/jnci\/djae062","article-title":"Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study","volume":"116","author":"Friedman","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2026052722304558000_13.10.e013267.16","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1002\/cncr.30934","article-title":"Historical time to disease progression and progression-free survival in patients with recurrent\/refractory neuroblastoma treated in the modern era on Children\u2019s Oncology Group early-phase trials","volume":"123","author":"London","year":"2017","journal-title":"Cancer"},{"key":"2026052722304558000_13.10.e013267.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30355-8"},{"key":"2026052722304558000_13.10.e013267.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.508"},{"key":"2026052722304558000_13.10.e013267.19","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.20.00203","article-title":"Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children\u2019s Oncology Group","volume":"38","author":"Mody","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026052722304558000_13.10.e013267.20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1452"},{"key":"2026052722304558000_13.10.e013267.21","unstructured":"Dinutuximab with chemotherapy, surgery and stem cell transplantation for the treatment of children with newly diagnosed high risk neuroblastoma. 2025. Available: https:\/\/www.clinicaltrials.gov\/study\/NCT06172296"},{"key":"2026052722304558000_13.10.e013267.22","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12196223","article-title":"A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood","volume":"12","author":"Keyel","year":"2023","journal-title":"J Clin Med"},{"key":"2026052722304558000_13.10.e013267.23","doi-asserted-by":"crossref","unstructured":"Dalton GN , Kim W-J , Mabe NW , et al . 244\u2005Targeting gangliosides in pediatric cancer. SITC 38th Annual Meeting (SITC 2023) Abstracts; November 2023 doi:10.1136\/jitc-2023-SITC2023.0244","DOI":"10.1136\/jitc-2023-SITC2023.0244"},{"key":"2026052722304558000_13.10.e013267.24","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/2767-9764.CRC-25-0293","article-title":"A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors","volume":"5","author":"DeSantes","year":"2025","journal-title":"Cancer Res Commun"},{"key":"2026052722304558000_13.10.e013267.25","unstructured":"Keyel M , Reynolds CP . HSAN is an anti-neuroblastoma monoclonal antibodythat binds to gfra2. advances in neuroblastoma research, abstract book. Washington DC, 2025:326."},{"key":"2026052722304558000_13.10.e013267.26","first-page":"471","article-title":"Enhancement of in vitro and in vivo anti-tumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor","volume":"2","author":"Fukuda","year":"1998","journal-title":"Int J Mol Med"},{"key":"2026052722304558000_13.10.e013267.27","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28851"},{"key":"2026052722304558000_13.10.e013267.28","doi-asserted-by":"crossref","unstructured":"Ansari IH , Shi LX , Erbe-Gurel AK , et al . Improving pediatric neuroblastoma immunotherapy outcome by using B7-H3 CARTcells in combination with low-dose external beam radiation therapy (EBRT):preclinical development in murine models. J Immunother Cancer 2024;12. doi:10.1136\/jitc-2024-SITC2024.0315","DOI":"10.1136\/jitc-2024-SITC2024.0315"},{"key":"2026052722304558000_13.10.e013267.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210859"},{"key":"2026052722304558000_13.10.e013267.30","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020"},{"key":"2026052722304558000_13.10.e013267.31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2021.10.016","article-title":"Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration","volume":"160","author":"Pearson","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026052722304558000_13.10.e013267.32","unstructured":"Study of efficacy and safety of tisagenlecleucel in children and young adults withhr b-all that is end-consolidation mrd positive. 2025. Available: https:\/\/clinicaltrials.gov\/study\/NCT03876769"},{"key":"2026052722304558000_13.10.e013267.33","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1016\/j.ymthe.2025.05.025","article-title":"Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells","volume":"33","author":"Giudice","year":"2025","journal-title":"Mol Ther"},{"key":"2026052722304558000_13.10.e013267.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0821-8"},{"key":"2026052722304558000_13.10.e013267.35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ymthe.2024.11.028","article-title":"ARI0003: Co-transduced CD19\/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma","volume":"33","author":"Bachiller","year":"2025","journal-title":"Mol Ther"},{"key":"2026052722304558000_13.10.e013267.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02893-z"},{"key":"2026052722304558000_13.10.e013267.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408771"},{"key":"2026052722304558000_13.10.e013267.38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1470-2045(25)00139-1","article-title":"Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial","volume":"26","author":"Syeda","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026052722304558000_13.10.e013267.39","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30735","article-title":"Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma","volume":"71","author":"Vayani","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"2026052722304558000_13.10.e013267.40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004834","article-title":"Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma","volume":"10","author":"Aiken","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026052722304558000_13.10.e013267.41","doi-asserted-by":"crossref","unstructured":"Rakhmilevich AL , Matthews J , Felder M , et al . AntiCD40 monoclonal antibody improves the efficacy of a current anti-gd2 chemoimmunotherapy regimen in a mouse neuroblastoma model. advances in neuroblastoma research. Washington DC, 2025 doi:10.1136\/jitc-2024-SITC2024.0707","DOI":"10.1136\/jitc-2024-SITC2024.0707"},{"key":"2026052722304558000_13.10.e013267.42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1767"},{"key":"2026052722304558000_13.10.e013267.43","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0823-6","article-title":"Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition","volume":"7","author":"Voeller","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026052722304558000_13.10.e013267.44","doi-asserted-by":"crossref","unstructured":"Erbe-Gurel AK , Feils AS , Winn N , et al . 714\u2005Anti-cd40 and epigenetic modifier inhibitors to augment treatment of high-risk neuroblastoma. SITC 39th Annual Meeting (SITC 2024) Abstracts; November 2024 doi:10.1136\/jitc-2024-SITC2024.0714","DOI":"10.1136\/jitc-2024-SITC2024.0714"},{"key":"2026052722304558000_13.10.e013267.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02297-5"},{"key":"2026052722304558000_13.10.e013267.46","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/1535-7163.MCT-24-0684","article-title":"Kinome Reprogramming of G2\/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma","volume":"24","author":"Matkar","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"2026052722304558000_13.10.e013267.47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2644"},{"key":"2026052722304558000_13.10.e013267.48","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"key":"2026052722304558000_13.10.e013267.49","doi-asserted-by":"crossref","first-page":"115708","DOI":"10.1016\/j.ejca.2025.115708","article-title":"The immune landscape of pediatric (extra)cranial solid tumors: A systematic review and integration of immunohistochemistry and single-cell RNA sequencing data","volume":"228","author":"Bergsma","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026052722304558000_13.10.e013267.50","unstructured":"Rossig C , Mackall CL . Tumor immunology and pediatric cancer. 9th edn. Lippincott Raven, Philadelphia, 2025."},{"key":"2026052722304558000_13.10.e013267.51","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041574","article-title":"Immunotherapies for Childhood Cancer","volume":"15","author":"Park","year":"2025","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026052722304558000_13.10.e013267.52","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001369"},{"key":"2026052722304558000_13.10.e013267.53","doi-asserted-by":"crossref","unstructured":"Cheung NK , Sondel PM . Neuroblastoma immunology and immunotherapy neuroblastoma. 2005.","DOI":"10.1007\/b137762"},{"key":"2026052722304558000_13.10.e013267.54","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115319","article-title":"From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies","volume":"26","author":"Amoozgar","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026052722304558000_13.10.e013267.55","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13394"},{"key":"2026052722304558000_13.10.e013267.56","doi-asserted-by":"crossref","first-page":"28059","DOI":"10.18632\/oncotarget.8574","article-title":"Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fc\u03b3 receptors","volume":"7","author":"Borlak","year":"2016","journal-title":"Oncotarget"},{"key":"2026052722304558000_13.10.e013267.57","doi-asserted-by":"crossref","unstructured":"Erbe AK , Feils AS , Hampton A , et al . Bispecific gd2 x b7-h3 antibody improves tumor targeting and reduces toxicity while maintaining efficacy for neuroblastoma. bioRxiv 2024. doi:10.1101\/2024.05.23.595588","DOI":"10.1101\/2024.05.23.595588"},{"key":"2026052722304558000_13.10.e013267.58","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20785-x","article-title":"Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma","volume":"12","author":"Moghimi","year":"2021","journal-title":"Nat Commun"},{"key":"2026052722304558000_13.10.e013267.59","doi-asserted-by":"publisher","DOI":"10.15698\/cst2019.06.188"},{"key":"2026052722304558000_13.10.e013267.60","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-019-0169-8","article-title":"Mesothelin as a biomarker for targeted therapy","volume":"7","author":"Lv","year":"2019","journal-title":"Biomark Res"},{"key":"2026052722304558000_13.10.e013267.61","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.3280"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:31:26Z","timestamp":1779946286000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,31]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/jitc-2025-013267"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013267","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}